Antisoma value slashed in half after failure of new cancer drug

One of the most advanced drugs to have been developed by a UK biotech has spectacularly failed its clinical trials, sending shares in the company that owns it down 50 per cent and raising questions over the viability of the entire industry.

Antisoma's pill was no more effective against ovarian cancer than a placebo, the company said yesterday, and the product is to be abandoned after 15 years of work costing an estimated £20m. The unequivocal judgement came as a disappointment to those who had hoped a successful outcome would give a boost to investor interest in the fragile biotech sector. It is also a blow to those who bought into a placing and open offer of Antisoma shares at 40p last November. Yesterday, they fell 24.5p to 20p.

More than 420 women in 17 countries took part in the trials and, although the data will be presented at cancer conferences in an attempt to assist understanding of the disease, there is no chance of it being tried in other cancers. Glyn Edwards, the chief executive, said: "It is a definitive result and there is no future for this drug in any of its indications."

The product, codenamed R1549 but previously known as pemtumomab, has had a chequered history. It was originally licensed to Abbott Laboratories, the US pharmaceuticals giant, but Abbott tried to renegotiate terms in 2002 after equivocal data from Phase II trials. It was taken up by Roche when the Swiss giant did its wide-ranging licensing deal with Antisoma in 2002.

Roche said the disappointment would not affect its relationship with Antisoma, which has, in effect, been annexed as a research and development laboratory for the Swiss group. It is funding earlier-stage trials of a breast cancer drug and has options over other products developed by Antisoma. Mr Edwards said Antisoma has more than two years of cash left, and this would most likely be augmented by milestone payments from Roche, but analysts said there was more pressure on him to buy in an extra product to bolster the pipeline of new drug.

The company raised £15.2m last year, which it said at the time would fund the existing pipeline. One investor who bought in at the placing - and sold out yesterday - said he had been buying "an option" on the success of R1549.

The failure of the product prompted handwringing across the UK biotech sector, whose failure to produce blockbuster drugs is often contrasted with the United States. Yesterday, Roche revealed that another of its partners, Genentech of San Francisco, had successfully completed trials of Tarceva for lung cancer.

Rare successes include Humira, a rheumatoid arthritis drug discovered using know-how at Cambridge Antibody Technology, but which is now the subject of a bitter dispute over royalties between CAT and Abbott, which developed it.

David Oxlade, the chief executive of Xenova, whose brain cancer drug Tariquidar was all but abandoned last year, said that the heavy focus investors had been putting on Antisoma's long-awaited trials results highlighted just how thin the UK industry's pipeline is. "The industry is 10-15 years behind the US. It is easier to obtain larger sums of money in the US than in Europe, so their companies have more money to build the depth and breadth of portfolio that allows you to survive the inevitable disappointments."

Andy Smith, the fund manager of the 3i Biosciences investment trust, worries that the biotech sector's modest recent bounce means it is nearer the top of the cycle of investor sentiment than the bottom.

Start your day with The Independent, sign up for daily news emails
sportWWE latest including Sting vs Triple H, Brock Lesnar vs Roman Reigns and The Undertaker vs Bray Wyatt
Arts and Entertainment
Louis Theroux: By Reason of Insanity takes him behind the bars again
tvBy Reason of Insanity, TV review
Arts and Entertainment
Cassetteboy's latest video is called Emperor's New Clothes rap
videoThe political parody genius duo strike again with new video
Arts and Entertainment
tvPoldark, TV review
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Retirement Coordinator - Financial Services

Negotiable: Recruitment Genius: To provide a prompt, friendly and efficient se...

Recruitment Genius: Annuities / Pensions Administrator

Negotiable: Recruitment Genius: You will be the first point of contact for all...

Ashdown Group: HR, Payroll & Benefits Officer - Altrincham - up to £24,000.

£18000 - £24000 per annum + benefits: Ashdown Group: HR, Payroll & Benefits Of...

Ashdown Group: Learning and Development Programme Manager

£35000 - £38000 per annum + benefits : Ashdown Group: A highly successful, int...

Day In a Page

No postcode? No vote

Floating voters

How living on a houseboat meant I didn't officially 'exist'
Louis Theroux's affable Englishman routine begins to wear thin

By Reason of Insanity

Louis Theroux's affable Englishman routine begins to wear thin
Power dressing is back – but no shoulderpads!

Power dressing is back

But banish all thoughts of Eighties shoulderpads
Spanish stone-age cave paintings 'under threat' after being re-opened to the public

Spanish stone-age cave paintings in Altamira 'under threat'

Caves were re-opened to the public
'I was the bookies’ favourite to be first to leave the Cabinet'

Vince Cable interview

'I was the bookies’ favourite to be first to leave the Cabinet'
Election 2015: How many of the Government's coalition agreement promises have been kept?

Promises, promises

But how many coalition agreement pledges have been kept?
The Gaza fisherman who built his own reef - and was shot dead there by an Israeli gunboat

The death of a Gaza fisherman

He built his own reef, and was fatally shot there by an Israeli gunboat
Saudi Arabia's airstrikes in Yemen are fuelling the Gulf's fire

Saudi airstrikes are fuelling the Gulf's fire

Arab intervention in Yemen risks entrenching Sunni-Shia divide and handing a victory to Isis, says Patrick Cockburn
Zayn Malik's departure from One Direction shows the perils of fame in the age of social media

The only direction Zayn could go

We wince at the anguish of One Direction's fans, but Malik's departure shows the perils of fame in the age of social media
Young Magician of the Year 2015: Meet the schoolgirl from Newcastle who has her heart set on being the competition's first female winner

Spells like teen spirit

A 16-year-old from Newcastle has set her heart on being the first female to win Young Magician of the Year. Jonathan Owen meets her
Jonathan Anderson: If fashion is a cycle, this young man knows just how to ride it

If fashion is a cycle, this young man knows just how to ride it

British designer Jonathan Anderson is putting his stamp on venerable house Loewe
Number plates scheme could provide a licence to offend in the land of the free

Licence to offend in the land of the free

Cash-strapped states have hit on a way of making money out of drivers that may be in collision with the First Amendment, says Rupert Cornwell
From farm to fork: Meet the Cornish fishermen, vegetable-growers and butchers causing a stir in London's top restaurants

From farm to fork in Cornwall

One man is bringing together Cornwall's most accomplished growers, fishermen and butchers with London's best chefs to put the finest, freshest produce on the plates of some of the country’s best restaurants
Robert Parker interview: The world's top wine critic on tasting 10,000 bottles a year, absurd drinking notes and New World wannabes

Robert Parker interview

The world's top wine critic on tasting 10,000 bottles a year, absurd drinking notes and New World wannabes
Don't believe the stereotype - or should you?

Don't believe the stereotype - or should you?

We exaggerate regional traits and turn them into jokes - and those on the receiving end are in on it too, says DJ Taylor